Evidence map›Paper›PMID 35431238›Full record

ArticleJournal of Alzheimer's disease : JAD2022

Frontal Metabolites and Alzheimer's Disease Biomarkers in Healthy Older Women and Women Diagnosed with Mild Cognitive Impairment.

Antoine Hone-Blanchet, Anastasia Bohsali, Lisa C Krishnamurthy, Salman S Shahid, Qixiang Lin, Liping Zhao, Aditya S Bisht, Samantha E John, David Loring, Felicia Goldstein and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. CEST imaging combined withAlzheimer's research & therapy · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Antoine Hone-BlanchetDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
Anastasia BohsaliDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
Lisa C KrishnamurthyDepartment of Physics & Astronomy, Georgia State University, Atlanta, GA, USA.
Salman S ShahidDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
Qixiang LinDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
Liping ZhaoDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Aditya S BishtDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
Samantha E JohnDepartment of Brain Health, Population Health & Health Equity Initiative, University of Nevada, Las Vegas, NV, USA.
David LoringDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
Felicia GoldsteinDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
Allan LeveyDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
James LahDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
Deqiang QiuDepartment of Radiology and Imaging Sciences, School of Medicine, Emory University, Atlanta, GA, USA.
Bruce CrossonDepartment of Neurology, School of Medicine, Emory University, Atlanta, GA, USA.
Emory University · USAthinoula A. Martinos Center for Biomedical Imaging · USAtlanta VA Health Care System · USGeorgia Institute of Technology · USGeorgia State University · USIndiana University · USUniversity of Nevada, Reno · US

Funding

The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's DiseaseR01AG070937 · NIA · EMORY UNIVERSITY · PI LAH, JAMES J · 2021 to 2025
$35.2M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Alvaro Alonso · 2020 to 2026
$29.0M
Cerebral hemodynamic impairment in symptomatic and asymptomatic Alzheimer's DiseaseR01AG072603 · NIA · EMORY UNIVERSITY · PI Deqiang Qiu · 2022 to 2026
$3.8M
Effects of Acute Exercise on Functional Magnetic Resonance Spectroscopy Measures of GABA in Aging and Chronic StrokeI21RX003581 · VA · VETERANS HEALTH ADMINISTRATION · PI KRISHNAMURTHY, LISA C. · 2021 to 2022
–
NIA NIH HHS P30 AG066511NIA NIH HHS R01 AG070937NIA NIH HHS R01 AG072603RRD VA I21 RX003581
6 · The paper itself

Abstract

backgroundWomen account for two thirds of the prevalence and incidence of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Evidence suggest that sex may differently influence the expression of proteins amyloid-beta (Aβ1-42) and tau, for which early detection is crucial in prevention of the disease.

objectiveWe investigated the effect of aging and cerebrospinal fluid (CSF) levels of Aβ1-42 and tau on frontal metabolites measured with proton magnetic resonance spectroscopy (MRS) in a cohort of cognitively normal older women and women with MCI.

methods3T single-voxel MRS was performed on the medial frontal cortex, using Point Resolved Spectroscopy (PRESS) and Mescher-Garwood Point Resolved Spectroscopy (MEGA-PRESS) in 120 women (age range 50-85). CSF samples of Aβ1-42 and tau and scores of general cognition were also obtained.

resultsLevels of frontal gamma aminobutyric acid (GABA+) were predicted by age, independently of disease and CSF biomarkers. Importantly, levels of GABA+ were reduced in MCI patients. Additionally, we found that levels of N-acetylaspartate relative to myo-inositol (tNAA/mI) predicted cognition in MCI patients only and were not related to CSF biomarkers.

conclusionThis study is the first to demonstrate a strong association between frontal GABA+ levels and neurological aging in a sample consisting exclusively of healthy older women with various levels of CSF tau and Aβ1-42 and women with MCI. Importantly, our results show no correlation between CSF biomarkers and MRS metabolites in this sample.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersFemalegamma-Aminobutyric AcidHumansPeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersgamma-Aminobutyric AcidPeptide Fragmentstau ProteinsAgingcerebrospinal fluid biomarkersfrontal cortexgeneral cognitionmagnetic resonance spectroscopymild cognitive impairmentwomen’s health

Identifiers

PMID35431238
PMCPMC9795460
OpenAlexW4223506258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.